ALKERMES |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Apr. 09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
| Apr. 09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
Chart calendar ALKERMES
92051a19783daff3b582babb8e229f.HbRLuu2Ld5eUhCk4X4eLH63YFX1IFcCeNtN0Tqvr5eI.ZMwxiYHaNabRzkZcCOvxaZWAdiIqTfPqZopGG92Dva4wgzmN3OAd2KTQGQ~035fdbc3190e6ecfb60952551407a74d
Upcoming events on ALKERMES
Past events on ALKERMES
| 2024-02-15 08:00 am | Q4 2023 Earnings Call |
| 2024-02-15 07:00 am | Q4 2023 Earnings Release |
| 2024-01-10 02:15 pm | JPMorgan Healthcare Conference |
| 2023-11-29 10:00 am | Evercore ISI HealthCONx Conference |
| 2023-11-28 11:00 am | Piper Sandler Healthcare Conference |
| 2023-11-15 | Spin off |
| 2023-11-14 12:00 pm | Jefferies London Healthcare Conference |
| 2023-10-25 08:00 am | Q3 2023 Earnings Call |
| 2023-10-25 08:00 am | World Sleep Congress - Abstract No. -#1337 |
| 2023-10-25 07:00 am | Q3 2023 Earnings Release |
| 2023-10-23 05:00 pm | World Sleep Congress - Abstract No. -#1329 |
| 2023-10-23 08:13 am | World Sleep Congress - Abstract No. -#1600 |
| 2023-10-17 11:00 am | Investor Meeting |
| 2023-09-27 11:30 am | Cantor Global Healthcare Conference |
| 2023-09-11 11:20 am | Morgan Stanley Global Healthcare Conference |
| 2023-09-05 | Psych Congress - Poster No: #86 |
| 2023-09-05 | Psych Congress - Poster No: #147 |
| 2023-09-05 | Psych Congress - Poster No: #148 |
| 2023-09-05 | Psych Congress - Poster No: #157 |
| 2023-09-05 | Psych Congress - Poster No: #161 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1 171 1 164 0.56% | 1 039 1 027 1.15% | 1 174 1 158 1.35% | 1 112 1 097 1.37% | 1 663 1 632 1.9% | 1 518 |
|
EBITDA Million USD | Released Forecast Spread | -135 -42,5 -217.9% | -73,0 -51,1 -42.89% | 49,4 108 -54.45% | -64,4 -23,5 -173.53% | 487 383 27.06% | 510 |
|
EBIT Million USD | Released Forecast Spread | -175 -99,9 -75.64% | -112 -117 3.77% | -29,3 -20,7 -41.17% | -142 -138 -3.21% | 414 259 59.73% | 443 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -197 -136 -45.13% | -96,5 -86,5 -11.65% | -39,3 -69,0 43.07% | -167 -183 8.78% | 422 260 62.12% | 431 |
|
Net income Million USD | Released Forecast Spread | -197 -137 -43.16% | -111 -98,9 -12.12% | -48,2 -79,2 39.19% | -158 -166 4.41% | 356 265 34.32% | 348 |
|
EPS USD | Released Forecast Spread | -1,25 -0,87 -44.03% | -0,70 -0,62 -13.2% | -0,30 -0,49 38.57% | -0,97 -0,99 2.16% | 2,10 1,55 35.33% | 2,04 |
| Announcement Date | 13/02/20 | 11/02/21 | 16/02/22 | 16/02/23 | 15/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 324 307 5.84% | 279 256 8.8% | 276 269 2.68% | 252 271 -7.03% | 305 290 5.13% | 288 282 2% | 617 483 27.79% | 381 362 5.12% | 377 362 4.17% | 363 | 391 | 383 | 376 | 361 |
|
EBITDA Million USD | Released Forecast Spread | 23,5 19,5 20.65% | -7,39 -13,0 43.17% | -25,4 -31,0 18.09% | -51,5 | -0,91 6,50 -113.95% | -38,7 -40,0 3.26% | 67,0 43,0 55.74% | 78,1 80,8 -3.36% | 72,9 106 -31.41% | 143 | 164 | 142 | 137 | |
|
EBIT Million USD | Released Forecast Spread | 2,38 -25,7 109.29% | -26,6 -42,4 37.34% | -34,5 -50,5 31.77% | -60,6 -40,8 -48.65% | -20,6 -31,8 35.2% | -47,5 -40,9 -16.06% | 239 62,3 283.79% | 43,8 24,0 82.66% | 54,6 27,7 96.92% | 101 | 125 | 115 | 110 | 107 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,23 -33,2 100.68% | -45,0 -44,3 -1.65% | -33,3 -51,0 34.8% | -67,4 -45,6 -47.59% | -21,7 -40,8 46.86% | -47,9 -53,6 10.67% | 240 45,9 422.66% | 47,4 25,1 88.73% | 58,3 11,4 410.15% | 88,9 | 111 | 120 | 120 | |
|
Net income Million USD | Released Forecast Spread | 0,87 -38,2 102.29% | -35,9 -41,7 13.97% | -30,1 -42,4 28.92% | -64,0 -38,5 -66.08% | -28,3 -35,9 21.28% | -41,8 -53,2 21.37% | 237 245 -3.38% | 47,8 17,3 176.62% | 113 22,3 404.8% | 74,9 | 92,9 | 89,9 | 85,5 | |
|
EPS USD | Released Forecast Spread | 0,01 -0,21 104.71% | -0,22 -0,25 12% | -0,18 -0,21 13.32% | -0,39 -0,24 -63.58% | -0,17 -0,23 25.04% | -0,25 -0,32 22.18% | 1,38 1,48 -6.76% | 0,28 0,10 186.12% | 0,66 0,12 470.79% | 0,44 | 0,54 | 0,53 | 0,50 | |
| Announcement Date | 16/02/22 | 27/04/22 | 27/07/22 | 02/11/22 | 16/02/23 | 26/04/23 | 26/07/23 | 25/10/23 | 15/02/24 | - | - | - | - | - |
More events
Past sector events for ALKERMES
| Today | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
- Stock Market
- Equities
- ALKS Stock
- Stock
- Calendar ALKERMES
